Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin

Archive ouverte

Ferreira, João Pedro | Zannad, Faiez | Butler, Javed | Filippatos, Gerasimos | Pocock, Stuart | Iwata, Tomoko | Sumin, Mikhail | Zeller, Cordula | Januzzi, James, L | Anker, Stefan, D | Packer, Milton

Edité par CCSD ; Elsevier/American College of Cardiology -

International audience. BACKGROUND Patients with a recent heart failure (HF) hospitalization have a high risk of rehospitalization and mortality. Early treatment may have a substantial impact on patient outcomes. OBJECTIVES The study sought to study the outcomes and effect of empagliflozin according to timing of prior HF hospitalization. METHODS EMPEROR-Pooled (EMPEROR-Reduced (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction) and EMPEROR-Preserved (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction) combined) included 9,718 HF patients who were grouped according to the recency of HF hospitalization (none, <3 months, 3-6 months, 6-12 months, >12 months). The primary outcome was a composite of time to first of HF hospitalization or cardiovascular death, over a median follow-up of 21 months. RESULTS The primary outcome event rates (per 100 person-years) in the placebo group were 26.7, 18.1, 13.7, and 2.8 for patients hospitalized within 3 months, 3-6 months, 6-12 months, and >12 months, respectively. The relative risk reduction of primary outcome events with empagliflozin was similar across HF hospitalization categories (P interaction ¼ 0.67). The primary outcome absolute risk reduction was more pronounced among patients with a recent HF hospitalization but without statistical heterogeneity of treatment effect: À6.9, À5.5, À0.8, and À0.6 events prevented per 100 person-years for patients hospitalized within <3 months, 3-6 months, 6-12 months, and >12 months, respectively, and À2.4 events prevented per 100 person-years of follow-up in those without a prior HF hospitalization (P interaction ¼ 0.64). Empagliflozin was safe irrespective of HF hospitalization recency. CONCLUSIONS Patients with a recent HF hospitalization have a high risk of events. Empagliflozin reduced HF events regardless of HF hospitalization recency.

Suggestions

Du même auteur

Patiromer and MRA Doses in Patients With Current or Past Hyperkalemia

Archive ouverte | Ferreira, João Pedro | CCSD

International audience. No abstract available

Proteomics for understanding progression to heart failure in chronic kidney disease: promising but still not there

Archive ouverte | Zannad, Faiez | CCSD

International audience

We Need Simpler and More Integrated Guidelines in Cardio-Kidney-Metabolic Diseases

Archive ouverte | Ferreira, João Pedro | CCSD

International audience

Chargement des enrichissements...